Boji Pharmaceutical announced that recently, its wholly-owned subsidiary, Xinglin Traditional Chinese Medicine Technology Co., Ltd. received the “A Liver Targeted Alkylating Agent and Its Application” invention patent certificate issued by the State Intellectual Property Office. The certificate number is No. 8613214, and the patent number is ZL20211668101.7. The application date is December 23, 2022, and the authorization announcement date is December 30, 2025. The patent has good application prospects in treating liver-related cancers. Although it has no significant impact on business performance, it is conducive to technological innovation and competitiveness.

Boji Pharmaceutical announced that recently, its wholly-owned subsidiary, Xinglin Traditional Chinese Medicine Technology Co., Ltd. received the “A Liver Targeted Alkylating Agent and Its Application” invention patent certificate issued by the State Intellectual Property Office. The certificate number is No. 8613214, and the patent number is ZL20211668101.7. The application date is December 23, 2022, and the authorization announcement date is December 30, 2025. The patent has good application prospects in treating liver-related cancers. Although it has no significant impact on business performance, it is conducive to technological innovation and competitiveness.